Prognostic analysis of acute exacerbations of hepatitis-B after chemotherapy in combination with rituximab in 19 patients with lymphoma
Authors:
- 14 July 2010
- journal article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 51 (9) , 1678-1685
Abstract
The prognosis and management of acute exacerbations of hepatitis-B in patients with lymphoma after chemotherapy in combination with rituximab remain unclear. Here, we describe 19 Chinese patients with lymphoma who suffered this complication, in order to analyze their clinical characteristics. Receiver operating characteristic analysis and Kaplan-Meier survival analysis were utilized to determine potential prognostic factors. We found that key prognostic factors included the peak prothrombin time (PT), international normalized ratio (INR), and total bilirubin (TB), as well as the PT and INR on admission and the interval between acute exacerbation of hepatitis-B and the last cycle of chemotherapy. Moreover, our data suggested that shorter interval between the last cycle of rituximab and acute exacerbation of hepatitis-B might be another prognostic indicator of inferior survival. Our results revealed that the severity of hepatic damage and the interval between the last cycle of chemotherapy and hepatitis flare were the major prognostic factors of an acute exacerbation of hepatitis-B induced by immunochemotherapy. Prophylactic antiviral and rescue antiviral therapy remain to be further characterized.Keywords
This publication has 23 references indexed in Scilit:
- Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenanceHaematologica, 2009
- Hepatitis B Virus Reactivation in Lymphoma Patients With Prior Resolved Hepatitis B Undergoing Anticancer Therapy With or Without RituximabJournal of Clinical Oncology, 2009
- EASL Clinical Practice Guidelines: Management of chronic hepatitis BJournal of Hepatology, 2009
- Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphomaBMC Cancer, 2008
- A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: A randomized trialHepatology, 2008
- Chronic hepatitis BHepatology, 2007
- Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphomaBritish Journal of Dermatology, 2006
- RituximabDrugs, 2006
- AASLD position paperHepatology, 2005
- Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapyBlood, 2003